Joshua J. Meeks

Also affiliated with Jesse Brown VA Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 23 papers. Top paper: “Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes”.

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Nature Reviews Urology(2020)10.1038/s41585-020-0304-1

N/A

0.794DataRank · unranked

198 citations

Hikmat Al‐Ahmadie, Bishoy M. Faltas, John A. Taylor, Thomas W. Flaig, David J. DeGraff +5 more

A simplified nomogram to assess risk of bladder cancer in patients with a new diagnosis of microscopic hematuria

Urologic Oncology Seminars and Original Investigations(2020)10.1016/j.urolonc.2019.12.010

N/A

0DataRank · unranked

20 citations

Alfred Rademaker, Joshua J. Meeks, Richard S. Matulewicz

A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps607

N/A

0DataRank · unranked

11 citations

Ali Shilatifard, Stephen D. Miller, Alicia K. Morgans, David James VanderWeele, Masha Kocherginsky +2 more

Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5028

N/A

0DataRank · unranked

4 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +11 more

Methodology for in vitro Assessment of Human T Cell Activation and Blockade

BIO-PROTOCOL(2020)10.21769/bioprotoc.3644

N/A

0DataRank · unranked

0 citations

Igal Ifergan, Ming‐Yi Chiang, Joshua J. Meeks, Stephen D. Miller, Joseph R. Podojil

γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer

Cancer Immunology Research(2021)10.1158/2326-6066.cir-21-0285

N/A

0DataRank · unranked

19 citations

Neelam Mukherjee, Zhen‐Ju Shu, Ryan M. Reyes, Joshua J. Meeks, David J. McConkey +4 more

EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps500

N/A

0DataRank · unranked

4 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)—An ECOG-ACRIN and NRG Collaboration.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4590

N/A

0DataRank · unranked

0 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more

Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy

Frontiers in Immunology(2022)10.3389/fimmu.2022.887649

N/A

0DataRank · unranked

18 citations

Andrew C. Cogswell, Ming‐Yi Chiang, Valerie Eaton, Igal Ifergan, Tobias Neef +11 more

An Evaluation of Peer-Rated Surgical Skill and its Relationship With Detrusor Muscle Sampling in Transurethral Resection of Bladder Tumor

Urology(2022)10.1016/j.urology.2022.07.057

N/A

0DataRank · unranked

2 citations

Oliver S. Ko, Reiping Huang, Amanda X. Vo, Kyle Tsai, Jeremy Lai +10 more

Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4506

N/A

0DataRank · unranked

7 citations

Melissa Plets, Gareth Morrison, Alexander Cunha, Steven Cen, Suhn K. Rhie +11 more

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

Frontiers in Immunology(2020)10.3389/fimmu.2020.01185

N/A

0DataRank · unranked

228 citations

April Bell, Erik Ladomersky, Kristen L. Lauing, Lakshmi Reddy Bollu, Jeffrey A. Sosman +11 more

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps591

N/A

0DataRank · unranked

1 citations

Melissa Plets, Michael A. Liss, Joshua J. Meeks, Daniel P. Petrylak, Suzanne Cole +9 more

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps594

N/A

0DataRank · unranked

0 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0602

N/A

0DataRank · unranked

19 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +12 more

A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.506

N/A

0DataRank · unranked

7 citations

Masha Kocherginsky, Parminder Singh, Zin Myint, Di Jiang, Elizabeth Wulff‐Burchfield +5 more

Data from γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer

(2023)10.1158/2326-6066.c.6550607

N/A

0DataRank · unranked

0 citations

Neelam Mukherjee, Zhen‐Ju Shu, Ryan M. Reyes, Joshua J. Meeks, David J. McConkey +4 more

Genomic and transcriptomic profiling of high-risk bladder cancer reveals diverse molecular and microenvironment ecosystems

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.12.21.629010

N/A

0DataRank · unranked

1 citations

Yanni Yu, Noah Frydenlund, Erik Z. Li, Bonnie Choy, Sarki A. Abdulkadir +2 more

Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?

European Urology Focus(2025)10.1016/j.euf.2025.11.014

N/A

0DataRank · unranked

1 citations

Joshua J. Meeks

Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.10.015

N/A

0DataRank · unranked

1 citations

Thomas Powles, Joshua J. Meeks

STING and IFNalpha/beta receptor are required for antigen-specific apoptotic cell-induced peripheral tolerance 3152

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.985

N/A

0DataRank · unranked

0 citations

Andrew C. Cogswell, Tobias Neef, Ming-Yi Chiang, Derrick McCarthy, Adam Elhofy +4 more

Standardizing time-to-event reporting in single-arm BCG-unresponsive registration trials: a case for Kaplan–Meier

Annals of Oncology(2025)10.1016/j.annonc.2025.11.010

N/A

0DataRank · unranked

0 citations

Joshua J. Meeks, Thomas Powles, Todd M. Morgan, Steven Monda

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4617

N/A

0DataRank · unranked

4 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more